Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last501 to 520 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| S-268019-b vs Placebo: serious adverse events | 154 of 9,083 136 of 8,435 | 0.1 points -0.3 to 0.5 | 17,518 | NCT05212948 A Study of S-268019 for the Prevention of COVID-19 |
| Clostridium Difficile Vaccine vs Placebo: deaths from any cause | 369 of 8,722 362 of 8,718 | 0.1 points -0.5 to 0.7 | 17,440 | NCT03090191 Clostridium Difficile Vaccine Efficacy Trial |
| Clostridium Difficile Vaccine vs Placebo: Number of Participants Reporting Serious Adverse Events (SAEs) | 719 of 8,722 722 of 8,718 | -0.0 points -0.9 to 0.8 | 17,440 | NCT03090191 Clostridium Difficile Vaccine Efficacy Trial |
| Clostridium Difficile Vaccine vs Placebo: serious adverse events | 719 of 8,722 722 of 8,718 | -0.0 points -0.9 to 0.8 | 17,440 | NCT03090191 Clostridium Difficile Vaccine Efficacy Trial |
| Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic Stroke | 756 of 8,582 803 of 8,578 | -0.6 points -1.4 to 0.3 | 17,160 | NCT01730534 Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events |
| Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure. | 417 of 8,582 496 of 8,578 | -0.9 points -1.6 to -0.3 | 17,160 | NCT01730534 Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events |
| Dapa 10 mg vs Placebo: Subjects Included in the Renal Composite Endpoint: Confirmed Sustained ≥40% Decrease in eGFR to eGFR <60 ml/Min/1.73m2 and/or ESRD and/or Renal or CV Death. | 370 of 8,582 480 of 8,578 | -1.3 points -1.9 to -0.6 | 17,160 | NCT01730534 Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events |
| Dapa 10 mg vs Placebo: Subjects Included in the Endpoint of All-cause Mortality. | 529 of 8,582 570 of 8,578 | -0.5 points -1.2 to 0.3 | 17,160 | NCT01730534 Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events |
| Dapa 10 mg vs Placebo: deaths from any cause | 529 of 8,582 570 of 8,578 | -0.5 points -1.2 to 0.3 | 17,160 | NCT01730534 Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events |
| Dapa 10 mg vs Placebo: serious adverse events | 3,205 of 8,574 3,418 of 8,569 | -2.5 points -4.0 to -1.0 | 17,143 | NCT01730534 Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events |
| Standard Implementation vs Intensive Implementation: deaths from any cause | 482 of 5,275 855 of 11,758 | 1.9 points 1.0 to 2.8 | 17,033 | NCT02765412 PrOVE QUERI Project #1 |
| Conventional vs suPAR: All Cause Mortality | 1,126 of 7,901 1,241 of 8,900 | 0.3 points -0.7 to 1.4 | 16,801 | NCT02643459 Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage |
| Conventional vs suPAR: Number of Discharges From the Emergency Room Within 24 Hours | 3,934 of 7,901 4,352 of 8,900 | 0.9 points -0.6 to 2.4 | 16,801 | NCT02643459 Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage |
| Conventional vs suPAR: Number of Patients With an Admission to the Intensive Care Unit | 1,027 of 7,901 1,157 of 8,900 | -0.0 points -1.0 to 1.0 | 16,801 | NCT02643459 Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage |
| Conventional vs suPAR: Number of Patients With New Cancer Diagnosis in Control vs Intervention Groups | 687 of 7,901 917 of 8,900 | -1.6 points -2.5 to -0.7 | 16,801 | NCT02643459 Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage |
| Conventional vs suPAR: Number of Admissions to the Medical Ward | 3,500 of 7,901 3,738 of 8,900 | 2.3 points 0.8 to 3.8 | 16,801 | NCT02643459 Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage |
| Conventional vs suPAR: Number of Readmissions | 687 of 7,901 917 of 8,900 | -1.6 points -2.5 to -0.7 | 16,801 | NCT02643459 Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage |
| Conventional vs suPAR: deaths from any cause | 1,126 of 7,901 1,241 of 8,900 | 0.3 points -0.7 to 1.4 | 16,801 | NCT02643459 Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage |
| Conventional vs suPAR: All Cause Mortality | 319 of 7,901 359 of 8,900 | 0.0 points -0.6 to 0.6 | 16,801 | NCT02643459 Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage |
| Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Antibiotic Choice for Pediatric Acute Otitis Media | 7,498 of 9,020 6,828 of 7,778 | -4.7 points -5.7 to -3.6 | 16,798 | NCT06027593 Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=26
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT05212948-sae",
"title": "S-268019-b vs Placebo: serious adverse events",
"summary": "154 of 9083 against 136 of 8435; risk difference 0.1 points, 95% interval -0.3 to 0.5; NCT05212948, A Study of S-268019 for the Prevention of COVID-19",
"record": "/library/comparisons/NCT05212948-sae",
"nct_id": "NCT05212948",
"kind": "serious-adverse-events",
"participants": 17518,
"risk_difference": {
"value": 0.0008314548417051697,
"lower": -0.0029827504738518347,
"upper": 0.004619229554729929
},
"group_1": "154 of 9,083",
"group_2": "136 of 8,435",
"difference": "0.1 points",
"interval": "-0.3 to 0.5",
"trial_title": "A Study of S-268019 for the Prevention of COVID-19"
},
{
"id": "NCT03090191-deaths",
"title": "Clostridium Difficile Vaccine vs Placebo: deaths from any cause",
"summary": "369 of 8722 against 362 of 8718; risk difference 0.1 points, 95% interval -0.5 to 0.7; NCT03090191, Clostridium Difficile Vaccine Efficacy Trial",
"record": "/library/comparisons/NCT03090191-deaths",
"nct_id": "NCT03090191",
"kind": "deaths",
"participants": 17440,
"risk_difference": {
"value": 0.0007835252074491414,
"lower": -0.005176173487484304,
"upper": 0.0067450801822503915
},
"group_1": "369 of 8,722",
"group_2": "362 of 8,718",
"difference": "0.1 points",
"interval": "-0.5 to 0.7",
"trial_title": "Clostridium Difficile Vaccine Efficacy Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=27",
"request_id": "SslZgtMFKTLHQ99s"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant